Cogent Biosciences, Inc.
COGT
$34.03
-$0.35-1.00%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -102.49M | -80.93M | -73.53M | -71.99M | -67.93M |
| Total Depreciation and Amortization | 1.14M | 1.15M | 1.16M | 1.14M | 1.11M |
| Total Amortization of Deferred Charges | 238.00K | 363.00K | -- | -- | -- |
| Total Other Non-Cash Items | 21.88M | 10.37M | 10.00M | 9.05M | 7.37M |
| Change in Net Operating Assets | 132.00K | 4.76M | 7.84M | -4.72M | -1.13M |
| Cash from Operations | -79.11M | -64.29M | -54.54M | -66.51M | -60.58M |
| Capital Expenditure | -811.00K | -65.00K | -131.00K | -547.00K | -75.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -321.96M | -154.98M | 9.04M | 69.93M | 61.75M |
| Cash from Investing | -322.77M | -155.05M | 8.91M | 69.38M | 61.67M |
| Total Debt Issued | 223.10M | 0.00 | 49.29M | -- | -- |
| Total Debt Repaid | -54.64M | 2.07M | -2.07M | -- | -- |
| Issuance of Common Stock | 494.62M | 231.90M | 705.00K | 24.97M | -- |
| Repurchase of Common Stock | -48.90M | -- | -- | -- | -11.57M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -25.52M | -16.60M | -700.00K | -- | 11.60M |
| Cash from Financing | 588.67M | 217.37M | 47.23M | 24.97M | 26.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 186.80M | -1.97M | 1.60M | 27.84M | 1.12M |